An educational live and enduring activity provided by i3 Health has demonstrated increased expertise and learning outcomes for treatment of patients with prostate cancer. Prostate cancer is the most common cancer in American men, seeing an average of 1 out of 8 men being diagnosed with it within their lifetime. The typical treatment for progressive prostate disease is androgen deprivation therapy (ADT); however, it is common for prostate cancer to become castration-resistant or resistant to ADT....

An educational live and enduring activity provided by i3 Health has demonstrated significant learning outcomes for the management and treatment of patients with myelofibrosis. Myelofibrosis, considered a form of chronic leukemia, is a rare type of myeloproliferative neoplasm. An estimated one-third of individuals who have myelofibrosis will not show any symptoms in the early stages of the disorder, which can last many years. However, as the disease develops, they will begin to exhibit symptoms s...

An educational live and enduring activity provided by i3 Health has demonstrated significant learning outcomes for treatment of patients with advanced non-Hodgkin lymphoma (NHL). The live activity, which was presented virtually at the 4th Annual GLAONS Oncology Care Summit, used a competitive, team-based "game show" format to explore the latest strategies and expert perspectives in treatment of patients with advanced NHL, including subtypes of follicular lymphoma (FL) and chronic lymphocytic leu...

An educational enduring activity provided by i3 Health demonstrated significant learning outcomes in the selection of treatment for patients with anaplastic lymphoma kinase (ALK)–positive advanced non–small cell lung cancer (NSCLC). This activity was created to advise clinicians on the development of individualized treatment plans based on the best available evidence and emerging guideline recommendations. Lung cancer is the second most common cancer in the United States, and the first most dead...

An educational activity provided by i3 Health has revealed significant learning gains in the knowledge of novel treatment strategies for metastatic colorectal cancer (mCRC). The activity was presented virtually at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2020 and was made available as an enduring online activity. Colorectal cancer is the second leading cause of cancer death among women and men in the United States and is the third most diagnosed cancer worldwide. In the...